RDIF, Panacea Biotec launch production of Sputnik V vaccine in India
The first batch of the Covid-19 vaccine produced at Panacea Biotec's facilities at Baddi in Himachal Pradesh will be shipped to Russia's Gamaleya Center for quality control.
Vials of Sputnik V (File photo) The Russian Direct Investment Fund (RDIF) and Indian drug firm Panacea Biotec on Monday announced the launch of production of the Sputnik V coronavirus vaccine in India.
The first batch of the COVID-19 vaccine produced at Panacea Biotec’s facilities at Baddi in Himachal Pradesh will be shipped to the Russia’s Gamaleya Center for quality control.
Full-scale production of the vaccine is expected to start this summer, RDIF and Panacea Biotec said in a joint statement.
As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V, it added.
“Launch of production in India in partnership with Panacea Biotec marks an important step in helping the country fight the pandemic,” RDIF chief executive Kirill Dmitriev said.
Share
